262 related articles for article (PubMed ID: 15638964)
21. Medical treatment of non-small-cell lung cancer.
Buter J; Giaccone G
Ann Oncol; 2005; 16 Suppl 2():ii229-32. PubMed ID: 15958463
[No Abstract] [Full Text] [Related]
22. Targeting the epidermal growth factor receptor.
El-Rayes BF; LoRusso PM
Br J Cancer; 2004 Aug; 91(3):418-24. PubMed ID: 15238978
[TBL] [Abstract][Full Text] [Related]
23. Epidermal Growth Factor Receptor Inhibition in Squamous Cell Carcinoma of the Head and Neck.
Machiels JP; Schmitz S
Hematol Oncol Clin North Am; 2015 Dec; 29(6):1011-32. PubMed ID: 26568545
[TBL] [Abstract][Full Text] [Related]
24. Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials.
Ciardiello F; De Vita F; Orditura M; De Placido S; Tortora G
Expert Opin Emerg Drugs; 2003 Nov; 8(2):501-14. PubMed ID: 14662002
[TBL] [Abstract][Full Text] [Related]
25. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab.
Brand TM; Iida M; Wheeler DL
Cancer Biol Ther; 2011 May; 11(9):777-92. PubMed ID: 21293176
[TBL] [Abstract][Full Text] [Related]
26. Epidermal growth factor receptor inhibition strategies in oncology.
Harari PM
Endocr Relat Cancer; 2004 Dec; 11(4):689-708. PubMed ID: 15613446
[TBL] [Abstract][Full Text] [Related]
27. Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how?
Juergens R; Brahmer J
Curr Oncol Rep; 2007 Jul; 9(4):255-64. PubMed ID: 17588349
[TBL] [Abstract][Full Text] [Related]
28. The role of inhibitors of the epidermal growth factor in management of head and neck cancer.
Brockstein B; Lacouture M; Agulnik M
J Natl Compr Canc Netw; 2008 Aug; 6(7):696-706. PubMed ID: 18691458
[TBL] [Abstract][Full Text] [Related]
29. Cetuximab in non-small cell lung cancer.
Ademuyiwa FO; Hanna N
Expert Opin Biol Ther; 2008 Jan; 8(1):107-13. PubMed ID: 18081540
[TBL] [Abstract][Full Text] [Related]
30. [Epidermal growth factor receptors (EGFR): a new target for anticancer therapy].
Gainet M; Guardiola E; Dufresne A; Pivot X
Cancer Radiother; 2003 Jun; 7(3):195-9. PubMed ID: 12834777
[TBL] [Abstract][Full Text] [Related]
31. Gefitinib versus cetuximab in lung cancer: round one.
Minna JD; Peyton MJ; Gazdar AF
J Natl Cancer Inst; 2005 Aug; 97(16):1168-9. PubMed ID: 16106015
[No Abstract] [Full Text] [Related]
32. Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling.
Harari PM; Huang SM
Semin Radiat Oncol; 2001 Oct; 11(4):281-9. PubMed ID: 11677653
[TBL] [Abstract][Full Text] [Related]
33. Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies.
Gialeli Ch; Kletsas D; Mavroudis D; Kalofonos HP; Tzanakakis GN; Karamanos NK
Curr Med Chem; 2009; 16(29):3797-804. PubMed ID: 19747140
[TBL] [Abstract][Full Text] [Related]
34. The role of the epidermal growth factor receptor in the treatment of colorectal carcinoma.
Waxman ES; Herbst RS
Semin Oncol Nurs; 2002 May; 18(2 Suppl 2):20-9. PubMed ID: 12053861
[TBL] [Abstract][Full Text] [Related]
35. EGFR-targeting monoclonal antibodies in head and neck cancer.
Astsaturov I; Cohen RB; Harari PM
Curr Cancer Drug Targets; 2006 Dec; 6(8):691-710. PubMed ID: 17168674
[TBL] [Abstract][Full Text] [Related]
36. Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors.
Caponigro F; Formato R; Caraglia M; Normanno N; Iaffaioli RV
Curr Opin Oncol; 2005 May; 17(3):212-7. PubMed ID: 15818163
[TBL] [Abstract][Full Text] [Related]
37. Growth factors and their receptors: new targets for prostate cancer therapy.
Barton J; Blackledge G; Wakeling A
Urology; 2001 Aug; 58(2 Suppl 1):114-22. PubMed ID: 11502465
[TBL] [Abstract][Full Text] [Related]
38. The role of cetuximab in the management of non-small-cell lung cancer.
Owonikoko TK; Sun SY; Ramalingam SS
Clin Lung Cancer; 2009 Jul; 10(4):230-8. PubMed ID: 19632939
[TBL] [Abstract][Full Text] [Related]
39. Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies.
Zhang W; Gordon M; Lenz HJ
Ann Med; 2006; 38(8):545-51. PubMed ID: 17438669
[TBL] [Abstract][Full Text] [Related]
40. Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations.
Perez-Torres M; Guix M; Gonzalez A; Arteaga CL
J Biol Chem; 2006 Dec; 281(52):40183-92. PubMed ID: 17082181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
